Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites

Nephrology Dialysis Transplantation

Volumn 20, Issue 8, 2005, Pages 1623-1629

  Kalambokis, Georgios ^a   Economou, Michalis ^a   Fotopoulos, Andreas ^a   Al Bokharhii, Jihad ^a   Katsaraki, Afroditi ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Ascites; Cirrhosis; Diuretic treatment; Octreotide; Renal function

Indexed keywords

ALDOSTERONE; CREATININE; DIURETIC AGENT; FUROSEMIDE; OCTREOTIDE; RENIN; SODIUM ION; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERRENINEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE BLIND PROCEDURE; SODIUM EXCRETION; URINE VOLUME;

ADULT; AGED; CHYLOUS ASCITES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; GASTROINTESTINAL AGENTS; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OCTREOTIDE; SODIUM; SPIRONOLACTONE; WATER;

EID: 26444580812     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh871     Document Type: Article

References (27)

1. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38: S69-S89
2. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1992; 15: 323-328
3. Garcia-Pagan JC, Salmeron JM, Feu F et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19: 1095-1099
4. Bataller R, Gines P, Arroyo V. Practical recommendations for the treatment of ascites and its complications. Drugs 1997; 54: 571-578
5. Bernardi M, Trevisani R, Capelli M et al. Study of renal function, renin-aldosterone axis and plasma electrolytes during diuretic treatment of patients with cirrhosis of the liver and ascites. Ital J Gastroenterol 1982; 14: 199-204
6. Hall JE. Control of sodium excretion by angiotensin II: Intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986; 250: R960-R972
7. Sieber CC, Lee FY, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal hypertensive rats. Hepatology 1996; 23: 1218-1223
8. Piccueta MP, Casamitjana R, Bosch J, Rodes J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: Role of hyperglucagonism. Am J Phsiol 1990; 258: G191-G195
9. Kurokawa K, Aponte G, Fujibayashi S, Yamada T. Somatostatin-like immunoreactivity in the glomerulus of rat kidney. Kidney Int 1983; 24: 754-757
10. Izumi Y, Honda M, Hartano M. Effect of somatostatin on plasma renin activity. Endocrinol Jpn 1979; 26: 389-394
11. Aguilera G, Parker DS, Gatt KJ. Characterization of somatostatin receptors in rat adrenal glomerulosa zone. Endocrinology 1982; 111: 1376-1382
12. Aguilera G, Parker DS, Gatt KJ. Somatostatin modulates effects of Angiotensin II in adrenal glomerulosa zone. Nature 1982; 292: 262-263
13. Rosenthal J, Escobar-Jimenez F, Raptis S, Pfeiffer EF. Inhibition of furosemide induced hyperreninaemia by growth hormone release inhibiting hormone in man. Lancet 1976; 1: 772-774
14. Rosenthal J, Escobar-Jimenez F, Raptis S. Prevention of somatostatin rise in blood pressure and plasma renin activity mediated by beta-receptor stimulation. Clin Endocrinol 1977; 6: 455-462
15. Arlart I, Rosenthal J, Pal S, Raptis S. Einfluss von Somatostatin auf Renin, Aldosteron and Blutdruck bei unilateraler renovaskularer Hypertonie. Verhandl Deutsh Gesell Inn Med 1978; 84: 824-827
16. Sieber C, Gnadinger M, del Pozo E, Shaw S, Weidmann P. Effect of a new Somatostatin analogue SMS 201-995 (sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988; 28: 25-32
17. Jones CR, Millar JA, Lawrie C, Summer DJ, Reid JL. Specific inhibition of aldosterone responses to endogenous and exogenous angiotensin II by somatostatin. Clin Endocrinol 1984; 21: 279-284
18. + retention in portal hypertensive rats. Gastroenterology 1993; 104: 575-579
19. Sabat M, Guarner C, Soriano G et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998; 43: 2184-2189
20. Kalambokis G, Economou M, Fotopoulos A et al. The effects of chronic treatment with octreotide vs octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005, 100: 879-885
21. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-176
22. Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-395
23. Blaufox MD. Measurement of renal function with radioactive materials. In: Blaufox MD, ed. Evaluation of renal function and disease with radionuclides. The upper urinary tract. Basel: Karger, 1989: 12-27
24. Van de Casteele M, Van Roey G, Nevens F et al. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in portal vein ligated rats. Hepatology 1996; 24: 1492-1496
25. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: Problems and pitfalls. Am J Kidney Dis 2003; 41: 269-278
26. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977; 233: F366-F372
27. Berthold H, del Rozo E. Antidiuretic effect of Sandostatin (SMS 201-995) in healthy volunteers. Acta Endocrinol (Copenh) 1989; 120: 708-714